Status:

COMPLETED

Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients

Lead Sponsor:

King Faisal Specialist Hospital & Research Center

Conditions:

Critical Illness

Sedation

Eligibility:

All Genders

14+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to investigate the efficacy and safety of a low dose ketamine infusion used in combination of standard of care in critically ill patients to test whether ketamine can help...

Detailed Description

Ketamine is used to produce sedation and relieve pain to minimize discomfort while a breathing tube placed in trachea (windpipe) and a machine (ventilator) used in the ICU. Several publications have s...

Eligibility Criteria

Inclusion

  • Adult ICU (Medical or surgical) patients (\> 14 years old)
  • Mechanically ventilated within the previous 24 hours and expected to remain intubated for more than 24 hours.
  • The patient requires ongoing sedative medication
  • No objection from the ICU attending MD for enrollment

Exclusion

  • Patients with a history of dementia or psychiatric disorders or on any anti-psychotics or anti-depressants medications at home
  • Pregnancy
  • Age \< 14 years old
  • Expected to need mechanical ventilation less than 24 hours
  • Known hypersensitivity to ketamine
  • Patient on dexmedetomidine as primary sedative agent prior to randomization
  • Patients with cardiogenic shock, heart failure, myocardial infarction
  • History of end-stage liver disease.
  • Proven or suspected primary neurological injury (traumatic brain injury, ischemic stroke, intracranial hemorrhage, spinal cord injury, anoxic brain injury)
  • Patients with persistent heart rate (HR) \> 150 bpm or systolic blood pressure (SBP) \>180 mmHg
  • Patients who assigned as do-not-resuscitate order (DNR) or expected to die within 24 hours
  • Patients on ECMO
  • Patients with status epilepticus patients who are receiving the ketamine infusion for refractory status epilepticus
  • Proven or suspected status asthmaticus
  • Patients with expected targeted RASS of -5 such as patients on continuous infusion neuromuscular blockade

Key Trial Info

Start Date :

August 28 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 6 2021

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT04075006

Start Date

August 28 2019

End Date

May 6 2021

Last Update

May 7 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

King Faisal Specialist Hospital and Research Centre

Riyadh, Saudi Arabia, 11211